LEXXNasdaqPharmaceutical PreparationsFiscal year ends August 31

Lexaria Bioscience Corp.

Financials through Q3 FY2026, quarter ended May 31, 2026Last filing: 10-Q on Jul 13, 2026

$2.60−0.26 (-9.09%)

Close on Oct 19, 2026

Market cap: $64.50M
P/E (TTM): –
Dividend yield: –

Lexaria Bioscience Corp. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-08-31	FY 2024 2024-08-31	FY 2023 2023-08-31	FY 2022 2022-08-31	FY 2021 2021-08-31	FY 2020 2020-08-31	FY 2019 2019-08-31	FY 2018 2018-08-31	FY 2017 2017-08-31	FY 2016 2016-08-31	FY 2015 2015-08-31	FY 2013 2013-10-31	FY 2012 2012-10-31	FY 2011 2011-10-31	FY 2010 2010-10-31
Revenue	0.71	0.46	0.23	0.26	0.72	0.31	0.22	0.43	0.06	0.04	0.01	–	–	–	–
Cost of Revenue	0.00	0.00	0.03	0.07	0.18	0.10	0.02	0.03	0.03	0.05	0.03	0.80	0.78	0.67	0.27
Gross Profit	0.70	0.46	0.19	0.18	0.55	0.22	0.20	0.41	0.03	0.00	-0.02	0.30	0.57	0.47	0.09
Research & Development	8.24	2.36	3.67	1.84	1.26	0.39	0.56	0.49	0.05	0.01	0.15	–	–	–	–
General & Administrative	4.35	3.85	3.06	4.96	4.97	3.98	0.30	0.22	0.13	0.13	0.02	0.01	0.00	0.01	0.00
Advertising Expenses	–	–	–	–	0.04	0.20	0.52	0.49	0.21	0.19	0.28	0.01	0.00	0.04	0.00
Operating Expenses	13	6.21	6.73	6.80	6.23	4.36	4.36	7.02	1.96	1.27	1.97	0.65	0.83	1.00	0.64
Operating Income	-12	-5.75	-6.53	-6.62	-5.69	–	–	–	–	-1.28	-1.98	–	–	–	–
Interest Expense	–	–	–	–	–	–	–	–	0.01	0.00	0.03	0.27	0.24	0.22	0.17
Interest & Investment Income	0.00	0.01	0.04	0.03	–	–	–	–	–	–	–	–	–	–	–
Other Non-Operating Income	-0.03	-0.06	-0.18	-0.76	–	–	–	–	–	–	–	–	–	–	–
Asset Impairment Charges	–	0.06	0.11	0	–	–	–	–	–	–	–	–	–	–	–
Gain (Loss) on Investments	0.03	–	–	–	–	-0.02	–	–	–	–	–	–	–	–	–
Gain (Loss) on Sale of Assets	–	–	0	-0.01	1.52	0	–	0.00	–	–	–	–	–	–	–
Pretax Income	-12	-5.81	-6.71	-7.38	-4.17	-3.99	-4.16	-6.61	-1.93	-1.27	–	–	–	–	–
Income Tax Expense	–	–	–	0	0.01	0.00	0.02	0	0	0	–	–	–	–	–
Income from Continuing Operations	–	–	–	-7.38	-4.16	-4.15	-4.16	-6.61	-1.93	-1.28	-1.93	-0.63	–	–	–
Income from Discontinued Operations	–	–	–	0	-0.02	0.06	–	–	–	0	0.05	0.28	–	–	–
Net Income incl. Noncontrolling Interests	-12	-5.81	-6.71	-7.38	4.19	–	–	–	–	–	–	–	–	–	–
Minority Interest in Earnings	-0.01	-0.01	-0.05	-0.11	-0.16	-0.15	-0.06	-0.01	-0.06	-0.06	-0.16	–	–	–	–
Net Income	-12	-5.80	-6.66	-7.27	-4.03	-4.08	4.10	6.60	-1.93	-1.28	-1.98	–	–	-0.54	-0.55
Net Income to Common	–	–	–	-7.27	-4.03	-3.93	-4.10	-6.61	-1.87	-1.21	-1.77	–	–	–	–
EPS (Basic)(per share)	–	–	–	–	-0.95	-1.47	-1.50	-2.70	-0.90	-0.90	-1.20	-0.60	-0.60	-1.20	–
EPS (Diluted)(per share)	-0.66	-0.47	-1.01	–	-0.95	-1.47	-1.50	-2.70	-0.90	-0.90	-1.20	-0.60	-0.60	-1.20	-1.20
Shares Outstanding (Basic, Weighted)(shares)	–	–	–	–	4.39	2.77	2.59	2.37	1.96	1.46	1.32	0.55	0.55	0.45	–
Shares Outstanding (Diluted, Weighted)(shares)	18	12	6.61	–	4.39	2.77	2.59	2.37	1.96	1.46	1.32	0.55	0.55	0.45	0.41
EBITDA	-12	-5.71	-6.39	-6.52	-5.58	–	–	–	–	–	–	–	–	–	–
Net Interest Income	–	0.01	0.04	–	–	–	–	–	–	–	–	–	–	–	–
Non-Interest Income	–	–	0.04	0	–	–	–	–	–	–	–	–	–	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at May 31, 2026

Profitability, TTM

Gross margin: 100.0%
Operating margin: -3973.2%
Net margin: -3985.6%
Return on equity, FY2025: -215.9%

Financial strength

Current ratio: 10.60
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 912.9%

Valuation

P/E ratio: –
Price to sales: 332.45
Price to book: 13.61
Dividend yield: –